These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 31220085)
1. Development of a prognostic risk score to aid antibiotic decision-making for children aged 2-59 months with World Health Organization fast breathing pneumonia in Malawi: An Innovative Treatments in Pneumonia (ITIP) secondary analysis. McCollum ED; Brown SP; Nkwopara E; Mvalo T; May S; Ginsburg AS PLoS One; 2019; 14(6):e0214583. PubMed ID: 31220085 [TBL] [Abstract][Full Text] [Related]
2. Placebo vs Amoxicillin for Nonsevere Fast-Breathing Pneumonia in Malawian Children Aged 2 to 59 Months: A Double-blind, Randomized Clinical Noninferiority Trial. Ginsburg AS; Mvalo T; Nkwopara E; McCollum ED; Ndamala CB; Schmicker R; Phiri A; Lufesi N; Izadnegahdar R; May S JAMA Pediatr; 2019 Jan; 173(1):21-28. PubMed ID: 30419120 [TBL] [Abstract][Full Text] [Related]
3. Amoxicillin for 3 or 5 Days for Chest-Indrawing Pneumonia in Malawian Children. Ginsburg AS; Mvalo T; Nkwopara E; McCollum ED; Phiri M; Schmicker R; Hwang J; Ndamala CB; Phiri A; Lufesi N; May S N Engl J Med; 2020 Jul; 383(1):13-23. PubMed ID: 32609979 [TBL] [Abstract][Full Text] [Related]
4. Methods for conducting a double-blind randomized controlled clinical trial of three days versus five days of amoxicillin dispersible tablets for chest indrawing childhood pneumonia among children two to 59 months of age in Lilongwe, Malawi: a study protocol. Ginsburg AS; May SJ; Nkwopara E; Ambler G; McCollum ED; Mvalo T; Phiri A; Lufesi N; Sadruddin S BMC Infect Dis; 2018 Sep; 18(1):476. PubMed ID: 30241517 [TBL] [Abstract][Full Text] [Related]
5. Can We Predict Oral Antibiotic Treatment Failure in Children with Fast-Breathing Pneumonia Managed at the Community Level? A Prospective Cohort Study in Malawi. King C; McCollum ED; Mankhambo L; Colbourn T; Beard J; Hay Burgess DC; Costello A; Izadnegahdar R; Lufesi N; Masache G; Mwansambo C; Nambiar B; Johnson E; Platt R; Mukanga D PLoS One; 2015; 10(8):e0136839. PubMed ID: 26313752 [TBL] [Abstract][Full Text] [Related]
6. A double blind community-based randomized trial of amoxicillin versus placebo for fast breathing pneumonia in children aged 2-59 months in Karachi, Pakistan (RETAPP). Jehan F; Nisar MI; Kerai S; Brown N; Balouch B; Hyder Z; Ambler G; Ginsburg AS; Zaidi AK BMC Infect Dis; 2016 Jan; 16():13. PubMed ID: 26758747 [TBL] [Abstract][Full Text] [Related]
7. Non-treatment of children with community health worker-diagnosed fast-breathing pneumonia in rural Malawi: exploratory subanalysis of a prospective cohort study. King C; Colbourn T; Mankhambo L; Beard J; Hay Burgess DC; Costello A; Izadnegahdar R; Lufesi N; Mwansambo C; Nambiar B; Johnson ES; Platt RW; Mukanga D; McCollum ED BMJ Open; 2016 Nov; 6(11):e011636. PubMed ID: 27852705 [TBL] [Abstract][Full Text] [Related]
8. Geographically linked risk factors for enrolment into a fast breathing child pneumonia trial in Lilongwe, Malawi: an Innovative Treatments in Pneumonia (ITIP) secondary analysis. Nkwopara E; Schmicker R; Mvalo T; May S; Ginsburg AS BMJ Open Respir Res; 2019; 6(1):e000414. PubMed ID: 31179007 [TBL] [Abstract][Full Text] [Related]
9. Chest radiography in children aged 2-59 months enrolled in the Innovative Treatments in Pneumonia (ITIP) project in Lilongwe Malawi: a secondary analysis. Mvalo T; McCollum ED; Fitzgerald E; Kamthunzi P; Schmicker RH; May S; Phiri M; Chirombo C; Phiri A; Ginsburg AS BMC Pediatr; 2022 Jan; 22(1):31. PubMed ID: 35012490 [TBL] [Abstract][Full Text] [Related]
10. Antibiotic treatment failure in children aged 1 to 59 months with World Health Organization-defined severe pneumonia in Malawi: A CPAP IMPACT trial secondary analysis. Mvalo T; Smith AG; Eckerle M; Hosseinipour MC; Kondowe D; Vaidya D; Liu Y; Corbett K; Nansongole D; Mtimaukanena TA; Lufesi N; McCollum ED PLoS One; 2022; 17(12):e0278938. PubMed ID: 36516197 [TBL] [Abstract][Full Text] [Related]
11. Randomized Trial of Amoxicillin for Pneumonia in Pakistan. Jehan F; Nisar I; Kerai S; Balouch B; Brown N; Rahman N; Rizvi A; Shafiq Y; Zaidi AKM N Engl J Med; 2020 Jul; 383(1):24-34. PubMed ID: 32609980 [TBL] [Abstract][Full Text] [Related]
12. Clinical Outcomes of Pneumonia and Other Comorbidities in Children Aged 2-59 Months in Lilongwe, Malawi: Protocol for the Prospective Observational Study "Innovative Treatments in Pneumonia". Ginsburg AS; May S; Nkwopara E; Ambler G; McCollum ED; Mvalo T; Phiri A; Lufesi N JMIR Res Protoc; 2019 Jul; 8(7):e13377. PubMed ID: 31359870 [TBL] [Abstract][Full Text] [Related]
13. Analysis of serious adverse events in a paediatric fast breathing pneumonia clinical trial in Malawi. Nkwopara E; Schmicker R; Mvalo T; Phiri M; Phiri A; Couasnon M; McCollum ED; Ginsburg AS BMJ Open Respir Res; 2019; 6(1):e000415. PubMed ID: 31548894 [TBL] [Abstract][Full Text] [Related]
14. Comparison of oral amoxicillin with placebo for the treatment of world health organization-defined nonsevere pneumonia in children aged 2-59 months: a multicenter, double-blind, randomized, placebo-controlled trial in pakistan. Hazir T; Nisar YB; Abbasi S; Ashraf YP; Khurshid J; Tariq P; Asghar R; Murtaza A; Masood T; Maqbool S Clin Infect Dis; 2011 Feb; 52(3):293-300. PubMed ID: 21189270 [TBL] [Abstract][Full Text] [Related]
15. Predictors of treatment failure for non-severe childhood pneumonia in developing countries--systematic literature review and expert survey--the first step towards a community focused mHealth risk-assessment tool? McCollum ED; King C; Hollowell R; Zhou J; Colbourn T; Nambiar B; Mukanga D; Burgess DC BMC Pediatr; 2015 Jul; 15():74. PubMed ID: 26156710 [TBL] [Abstract][Full Text] [Related]
16. Non-adherence to oral antibiotics for community paediatric pneumonia treatment in Malawi - A qualitative investigation. King C; Nightingale R; Phiri T; Zadutsa B; Kainja E; Makwenda C; Colbourn T; Stevenson F PLoS One; 2018; 13(10):e0206404. PubMed ID: 30379968 [TBL] [Abstract][Full Text] [Related]
17. Low rates of treatment failure in children aged 2-59 months treated for severe pneumonia: a multisite pooled analysis. Fox MP; Thea DM; Sadruddin S; Bari A; Bonawitz R; Hazir T; Bin Nisar Y; Qazi SA; Clin Infect Dis; 2013 Apr; 56(7):978-87. PubMed ID: 23264361 [TBL] [Abstract][Full Text] [Related]
18. A novel electronic algorithm using host biomarker point-of-care tests for the management of febrile illnesses in Tanzanian children (e-POCT): A randomized, controlled non-inferiority trial. Keitel K; Kagoro F; Samaka J; Masimba J; Said Z; Temba H; Mlaganile T; Sangu W; Rambaud-Althaus C; Gervaix A; Genton B; D'Acremont V PLoS Med; 2017 Oct; 14(10):e1002411. PubMed ID: 29059253 [TBL] [Abstract][Full Text] [Related]
19. Non-inferiority designs comparing placebo to a proven therapy for childhood pneumonia in low-resource settings. May S; Brown SP; Schmicker RH; Emerson SS; Nkwopara E; Ginsburg AS Clin Trials; 2020 Apr; 17(2):129-137. PubMed ID: 31814441 [TBL] [Abstract][Full Text] [Related]
20. A randomized controlled trial of hospital versus home based therapy with oral amoxicillin for severe pneumonia in children aged 3 - 59 months: The IndiaCLEN Severe Pneumonia Oral Therapy (ISPOT) Study. Patel AB; Bang A; Singh M; Dhande L; Chelliah LR; Malik A; Khadse S; BMC Pediatr; 2015 Nov; 15():186. PubMed ID: 26577943 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]